| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Crohn Disease | 56 | 2020 | 959 | 10.04 | Why? |
| Colitis, Ulcerative | 55 | 2020 | 1037 | 8.60 | Why? |
| Inflammatory Bowel Diseases | 66 | 2021 | 3209 | 8.09 | Why? |
| Gastrointestinal Agents | 21 | 2020 | 393 | 3.67 | Why? |
| Infliximab | 20 | 2019 | 502 | 3.64 | Why? |
| Biosimilar Pharmaceuticals | 7 | 2019 | 205 | 2.15 | Why? |
| Adalimumab | 11 | 2019 | 389 | 2.09 | Why? |
| Tumor Necrosis Factor-alpha | 19 | 2018 | 2483 | 1.66 | Why? |
| Cholangitis, Sclerosing | 4 | 2019 | 106 | 1.64 | Why? |
| Mesalamine | 6 | 2019 | 89 | 1.51 | Why? |
| Proctitis | 2 | 2019 | 16 | 1.50 | Why? |
| Intestines | 7 | 2019 | 817 | 1.35 | Why? |
| Biological Therapy | 6 | 2018 | 456 | 1.31 | Why? |
| Pyrroles | 4 | 2018 | 292 | 1.30 | Why? |
| Azathioprine | 7 | 2019 | 161 | 1.26 | Why? |
| Diffusion Magnetic Resonance Imaging | 2 | 2018 | 317 | 1.24 | Why? |
| Janus Kinases | 2 | 2019 | 414 | 1.11 | Why? |
| Patient Care Planning | 3 | 2018 | 582 | 1.09 | Why? |
| Remission Induction | 14 | 2019 | 950 | 1.08 | Why? |
| Antibodies, Monoclonal, Humanized | 16 | 2019 | 9335 | 1.07 | Why? |
| Immunosuppressive Agents | 17 | 2021 | 6331 | 1.05 | Why? |
| Piperidines | 4 | 2018 | 795 | 1.02 | Why? |
| Colitis | 5 | 2018 | 266 | 0.98 | Why? |
| Pyrimidines | 4 | 2018 | 1557 | 0.91 | Why? |
| Ustekinumab | 3 | 2018 | 216 | 0.89 | Why? |
| Intestinal Mucosa | 9 | 2018 | 1046 | 0.87 | Why? |
| Induction Chemotherapy | 3 | 2018 | 149 | 0.85 | Why? |
| Arthritis | 3 | 2019 | 288 | 0.82 | Why? |
| Medication Adherence | 4 | 2019 | 1270 | 0.80 | Why? |
| Budesonide | 3 | 2019 | 192 | 0.77 | Why? |
| Cost Savings | 2 | 2018 | 296 | 0.77 | Why? |
| Cholangiography | 1 | 2018 | 19 | 0.76 | Why? |
| Delphi Technique | 3 | 2018 | 1257 | 0.76 | Why? |
| Disability Evaluation | 3 | 2018 | 671 | 0.75 | Why? |
| Gastroenterology | 3 | 2020 | 1352 | 0.75 | Why? |
| Nocebo Effect | 1 | 2018 | 18 | 0.75 | Why? |
| Clinical Trials as Topic | 13 | 2020 | 7330 | 0.75 | Why? |
| Drug Monitoring | 5 | 2018 | 1408 | 0.74 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 7 | 2019 | 1454 | 0.71 | Why? |
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2018 | 40 | 0.71 | Why? |
| Protein Kinase Inhibitors | 2 | 2018 | 1585 | 0.69 | Why? |
| Wound Healing | 4 | 2018 | 424 | 0.69 | Why? |
| Proctocolectomy, Restorative | 1 | 2017 | 51 | 0.67 | Why? |
| Surgical Stomas | 1 | 2017 | 33 | 0.66 | Why? |
| Antibodies, Bispecific | 1 | 2018 | 207 | 0.64 | Why? |
| France | 20 | 2020 | 12074 | 0.64 | Why? |
| Lysophospholipids | 1 | 2017 | 74 | 0.63 | Why? |
| Feces | 8 | 2020 | 4235 | 0.63 | Why? |
| Patient Reported Outcome Measures | 3 | 2018 | 912 | 0.63 | Why? |
| Sphingosine | 1 | 2017 | 101 | 0.61 | Why? |
| Leukocyte L1 Antigen Complex | 4 | 2019 | 238 | 0.61 | Why? |
| Anemia, Iron-Deficiency | 1 | 2018 | 210 | 0.61 | Why? |
| Peer Review, Research | 1 | 2020 | 407 | 0.60 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2018 | 253 | 0.59 | Why? |
| Biological Products | 6 | 2019 | 2331 | 0.58 | Why? |
| Dysbiosis | 2 | 2018 | 685 | 0.56 | Why? |
| Spondylarthritis | 1 | 2017 | 174 | 0.56 | Why? |
| Endoscopy, Gastrointestinal | 4 | 2020 | 1545 | 0.56 | Why? |
| Pneumococcal Vaccines | 2 | 2018 | 571 | 0.55 | Why? |
| Magnetic Resonance Imaging | 5 | 2018 | 6551 | 0.55 | Why? |
| Immunocompromised Host | 3 | 2020 | 5150 | 0.53 | Why? |
| Humans | 149 | 2021 | 930598 | 0.52 | Why? |
| Disease Management | 3 | 2020 | 6841 | 0.52 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.51 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.51 | Why? |
| Health Status Indicators | 1 | 2017 | 341 | 0.51 | Why? |
| Arthritis, Rheumatoid | 2 | 2017 | 2043 | 0.50 | Why? |
| Review Literature as Topic | 1 | 2016 | 387 | 0.49 | Why? |
| Diagnostic Self Evaluation | 1 | 2017 | 394 | 0.48 | Why? |
| Gastrointestinal Neoplasms | 1 | 2017 | 392 | 0.48 | Why? |
| Mesentery | 1 | 2011 | 43 | 0.47 | Why? |
| Randomized Controlled Trials as Topic | 9 | 2019 | 10649 | 0.47 | Why? |
| Abdominal Fat | 1 | 2011 | 43 | 0.47 | Why? |
| Colorectal Neoplasms | 5 | 2019 | 1884 | 0.46 | Why? |
| Bacterial Translocation | 1 | 2011 | 39 | 0.46 | Why? |
| Antibodies, Monoclonal | 7 | 2018 | 8041 | 0.45 | Why? |
| Pneumococcal Infections | 2 | 2018 | 562 | 0.45 | Why? |
| Vaccines, Attenuated | 1 | 2017 | 952 | 0.45 | Why? |
| Self-Management | 1 | 2017 | 546 | 0.44 | Why? |
| Diarrhea | 2 | 2020 | 2743 | 0.43 | Why? |
| Constriction, Pathologic | 4 | 2019 | 212 | 0.42 | Why? |
| Autophagy | 1 | 2018 | 960 | 0.42 | Why? |
| Gastrointestinal Microbiome | 3 | 2018 | 1961 | 0.41 | Why? |
| Severity of Illness Index | 19 | 2020 | 48226 | 0.40 | Why? |
| Intestinal Obstruction | 3 | 2019 | 197 | 0.40 | Why? |
| Colonoscopy | 5 | 2018 | 738 | 0.39 | Why? |
| Immunotherapy | 3 | 2019 | 2421 | 0.38 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.37 | Why? |
| Colon | 3 | 2018 | 669 | 0.37 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.36 | Why? |
| Mercaptopurine | 2 | 2018 | 68 | 0.35 | Why? |
| Treatment Outcome | 30 | 2019 | 51732 | 0.34 | Why? |
| Smoking | 2 | 2020 | 3358 | 0.34 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.34 | Why? |
| Skin Diseases | 3 | 2019 | 2509 | 0.34 | Why? |
| Coronavirus Infections | 16 | 2020 | 253789 | 0.34 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.33 | Why? |
| Algorithms | 3 | 2018 | 7346 | 0.32 | Why? |
| Fibrosis | 3 | 2019 | 800 | 0.32 | Why? |
| Pneumonia, Viral | 15 | 2020 | 243684 | 0.31 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.31 | Why? |
| Infection Control | 6 | 2020 | 23131 | 0.31 | Why? |
| Hepatitis C | 2 | 2009 | 1514 | 0.30 | Why? |
| Intestinal Fistula | 2 | 2018 | 43 | 0.30 | Why? |
| Anti-Inflammatory Agents | 8 | 2020 | 6153 | 0.30 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.30 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.30 | Why? |
| Mucous Membrane | 2 | 2018 | 305 | 0.29 | Why? |
| Betacoronavirus | 14 | 2020 | 204454 | 0.29 | Why? |
| Biomedical Research | 3 | 2020 | 5270 | 0.29 | Why? |
| Drug Therapy, Combination | 8 | 2018 | 7268 | 0.27 | Why? |
| Dextran Sulfate | 3 | 2018 | 54 | 0.27 | Why? |
| Recurrence | 7 | 2019 | 3675 | 0.27 | Why? |
| Pandemics | 18 | 2020 | 389249 | 0.27 | Why? |
| Quality of Life | 8 | 2019 | 9820 | 0.27 | Why? |
| Integrins | 3 | 2019 | 158 | 0.27 | Why? |
| Influenza Vaccines | 2 | 2018 | 2941 | 0.27 | Why? |
| Endoscopy | 4 | 2018 | 1564 | 0.26 | Why? |
| Consensus | 5 | 2019 | 6345 | 0.26 | Why? |
| Escherichia coli | 1 | 2011 | 1547 | 0.26 | Why? |
| Global Health | 8 | 2020 | 13911 | 0.26 | Why? |
| Inflammation | 5 | 2020 | 13255 | 0.26 | Why? |
| Maintenance Chemotherapy | 3 | 2018 | 133 | 0.26 | Why? |
| Adult | 45 | 2019 | 244371 | 0.25 | Why? |
| Immunologic Factors | 2 | 2018 | 4206 | 0.25 | Why? |
| Glucocorticoids | 2 | 2019 | 4431 | 0.24 | Why? |
| Secondary Prevention | 2 | 2017 | 762 | 0.23 | Why? |
| Follow-Up Studies | 11 | 2019 | 17020 | 0.23 | Why? |
| Age of Onset | 3 | 2018 | 557 | 0.23 | Why? |
| Male | 52 | 2019 | 367725 | 0.22 | Why? |
| Practice Patterns, Physicians' | 4 | 2020 | 4927 | 0.22 | Why? |
| Hepatitis B | 1 | 2009 | 888 | 0.22 | Why? |
| Certolizumab Pegol | 2 | 2018 | 36 | 0.22 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 4 | 2019 | 1261 | 0.22 | Why? |
| Prospective Studies | 19 | 2019 | 43301 | 0.22 | Why? |
| Prognosis | 9 | 2020 | 32490 | 0.22 | Why? |
| Thioguanine | 2 | 2018 | 10 | 0.21 | Why? |
| Female | 51 | 2019 | 380317 | 0.21 | Why? |
| Dose-Response Relationship, Drug | 3 | 2018 | 3776 | 0.21 | Why? |
| Visual Analog Scale | 2 | 2018 | 151 | 0.21 | Why? |
| C-Reactive Protein | 3 | 2017 | 7972 | 0.21 | Why? |
| Vascular Endothelial Growth Factor C | 1 | 2019 | 8 | 0.21 | Why? |
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2019 | 8 | 0.21 | Why? |
| Tumor Escape | 1 | 2019 | 36 | 0.20 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.20 | Why? |
| Sexual Dysfunction, Physiological | 2 | 2018 | 89 | 0.20 | Why? |
| Multivariate Analysis | 4 | 2018 | 5440 | 0.20 | Why? |
| Dimensional Measurement Accuracy | 1 | 2018 | 56 | 0.19 | Why? |
| Fistula | 1 | 2018 | 34 | 0.19 | Why? |
| Seminal Plasma Proteins | 1 | 2018 | 3 | 0.19 | Why? |
| Drug Administration Schedule | 4 | 2018 | 2324 | 0.19 | Why? |
| Economics, Pharmaceutical | 1 | 2019 | 61 | 0.19 | Why? |
| Precision Medicine | 2 | 2019 | 1477 | 0.18 | Why? |
| Integrin alpha4 | 1 | 2018 | 21 | 0.18 | Why? |
| Reproductive Behavior | 1 | 2018 | 22 | 0.18 | Why? |
| Toll-Like Receptor 9 | 1 | 2018 | 72 | 0.18 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.18 | Why? |
| Anatomy, Cross-Sectional | 1 | 2017 | 7 | 0.18 | Why? |
| Drug Substitution | 2 | 2018 | 385 | 0.18 | Why? |
| Telemedicine | 3 | 2021 | 25032 | 0.17 | Why? |
| Ultrasonography | 3 | 2018 | 4409 | 0.17 | Why? |
| Arthritis, Experimental | 1 | 2017 | 44 | 0.17 | Why? |
| Research Subjects | 1 | 2020 | 178 | 0.17 | Why? |
| Mice, Knockout | 3 | 2018 | 1815 | 0.17 | Why? |
| Disease Progression | 6 | 2018 | 13580 | 0.17 | Why? |
| Interleukin-23 | 1 | 2017 | 64 | 0.17 | Why? |
| Calcineurin Inhibitors | 1 | 2018 | 218 | 0.17 | Why? |
| Unfolded Protein Response | 1 | 2018 | 134 | 0.17 | Why? |
| Interleukin-12 | 1 | 2017 | 156 | 0.16 | Why? |
| Colectomy | 2 | 2017 | 327 | 0.16 | Why? |
| Capsule Endoscopy | 1 | 2017 | 75 | 0.16 | Why? |
| Government Agencies | 1 | 2018 | 248 | 0.16 | Why? |
| Risk Factors | 13 | 2020 | 71621 | 0.16 | Why? |
| International Agencies | 1 | 2018 | 202 | 0.16 | Why? |
| Consensus Development Conferences as Topic | 1 | 2016 | 93 | 0.16 | Why? |
| Tumor Suppressor Proteins | 1 | 2017 | 165 | 0.16 | Why? |
| Endothelial Progenitor Cells | 1 | 2017 | 103 | 0.16 | Why? |
| Predictive Value of Tests | 7 | 2019 | 9537 | 0.16 | Why? |
| STAT Transcription Factors | 1 | 2017 | 173 | 0.16 | Why? |
| Membrane Transport Proteins | 1 | 2017 | 152 | 0.15 | Why? |
| Anus Neoplasms | 1 | 2017 | 123 | 0.15 | Why? |
| Phosphodiesterase 4 Inhibitors | 1 | 2017 | 112 | 0.15 | Why? |
| Docosahexaenoic Acids | 1 | 2017 | 145 | 0.15 | Why? |
| Retrospective Studies | 15 | 2018 | 105322 | 0.14 | Why? |
| Edema | 1 | 2018 | 333 | 0.14 | Why? |
| Incidence | 7 | 2020 | 25622 | 0.14 | Why? |
| European Union | 1 | 2018 | 565 | 0.14 | Why? |
| Logistic Models | 6 | 2018 | 9089 | 0.14 | Why? |
| Cost-Benefit Analysis | 3 | 2019 | 2259 | 0.14 | Why? |
| Multimodal Imaging | 1 | 2019 | 534 | 0.14 | Why? |
| Thalidomide | 1 | 2017 | 247 | 0.14 | Why? |
| Endothelium | 1 | 2018 | 460 | 0.14 | Why? |
| Young Adult | 19 | 2018 | 93724 | 0.14 | Why? |
| Cytokines | 2 | 2019 | 15010 | 0.13 | Why? |
| Surveys and Questionnaires | 9 | 2019 | 43792 | 0.13 | Why? |
| Curcumin | 1 | 2019 | 396 | 0.13 | Why? |
| Endoscopy, Digestive System | 1 | 2018 | 352 | 0.13 | Why? |
| Intestine, Small | 1 | 2017 | 336 | 0.13 | Why? |
| Animals | 14 | 2019 | 78931 | 0.13 | Why? |
| Mice, Inbred C57BL | 4 | 2019 | 5542 | 0.13 | Why? |
| Middle Aged | 29 | 2019 | 270681 | 0.13 | Why? |
| Goals | 1 | 2017 | 335 | 0.13 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.13 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.13 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.13 | Why? |
| Lymphoma | 1 | 2018 | 522 | 0.13 | Why? |
| Rectal Neoplasms | 1 | 2017 | 278 | 0.13 | Why? |
| Risk Assessment | 6 | 2020 | 25439 | 0.13 | Why? |
| Biomarkers | 8 | 2019 | 23361 | 0.13 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Influenza, Human | 2 | 2018 | 10779 | 0.12 | Why? |
| Receptors, Interleukin | 1 | 2012 | 83 | 0.12 | Why? |
| Reproducibility of Results | 6 | 2019 | 11304 | 0.12 | Why? |
| Environment | 1 | 2019 | 769 | 0.12 | Why? |
| Iron | 1 | 2018 | 619 | 0.12 | Why? |
| Virus Attachment | 1 | 2020 | 1259 | 0.12 | Why? |
| DNA | 1 | 2018 | 778 | 0.12 | Why? |
| New York | 1 | 2020 | 2488 | 0.12 | Why? |
| Ileitis | 1 | 2011 | 21 | 0.12 | Why? |
| Double-Blind Method | 3 | 2018 | 5988 | 0.11 | Why? |
| Osteoporosis | 2 | 2019 | 410 | 0.11 | Why? |
| Liver Function Tests | 1 | 2018 | 1325 | 0.11 | Why? |
| Physician-Patient Relations | 2 | 2020 | 1266 | 0.11 | Why? |
| Metabolic Syndrome | 1 | 2019 | 810 | 0.11 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2019 | 1153 | 0.11 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.11 | Why? |
| Mice | 6 | 2018 | 21357 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.11 | Why? |
| Digestive System Surgical Procedures | 1 | 2018 | 677 | 0.11 | Why? |
| Molecular Targeted Therapy | 2 | 2017 | 1579 | 0.11 | Why? |
| Activities of Daily Living | 1 | 2019 | 1530 | 0.10 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.10 | Why? |
| Inflammasomes | 1 | 2017 | 710 | 0.10 | Why? |
| Time Factors | 9 | 2019 | 31397 | 0.10 | Why? |
| Thionucleotides | 1 | 2008 | 6 | 0.10 | Why? |
| Perception | 2 | 2018 | 2827 | 0.10 | Why? |
| Image Processing, Computer-Assisted | 1 | 2018 | 1383 | 0.10 | Why? |
| Ferritins | 1 | 2018 | 2055 | 0.10 | Why? |
| Disease Models, Animal | 5 | 2018 | 10998 | 0.09 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.09 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 1458 | 0.09 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.09 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.09 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.09 | Why? |
| Environmental Exposure | 1 | 2019 | 1558 | 0.09 | Why? |
| Patient Safety | 2 | 2020 | 4885 | 0.09 | Why? |
| Antibodies, Fungal | 1 | 2007 | 49 | 0.09 | Why? |
| Clinical Decision-Making | 2 | 2019 | 3755 | 0.09 | Why? |
| Child | 6 | 2020 | 70012 | 0.09 | Why? |
| Drug Delivery Systems | 1 | 2017 | 1365 | 0.08 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.08 | Why? |
| Internationality | 2 | 2018 | 3297 | 0.08 | Why? |
| Italy | 3 | 2020 | 38444 | 0.08 | Why? |
| Registries | 4 | 2020 | 12327 | 0.08 | Why? |
| Interleukins | 1 | 2012 | 762 | 0.08 | Why? |
| Receptors, Cell Surface | 1 | 2011 | 586 | 0.08 | Why? |
| Lipopolysaccharides | 1 | 2011 | 848 | 0.08 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.08 | Why? |
| Research Design | 2 | 2020 | 5830 | 0.08 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.08 | Why? |
| Disabled Persons | 1 | 2017 | 1152 | 0.08 | Why? |
| Adrenal Cortex Hormones | 3 | 2018 | 6537 | 0.08 | Why? |
| Adolescent | 12 | 2018 | 86841 | 0.08 | Why? |
| Signal Transduction | 3 | 2017 | 7207 | 0.08 | Why? |
| Lymphocytes | 1 | 2019 | 3056 | 0.08 | Why? |
| Epitopes | 1 | 2018 | 4113 | 0.08 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.08 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.08 | Why? |
| Epidemiologic Methods | 1 | 2009 | 392 | 0.07 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.07 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.07 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.07 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Lymph Nodes | 1 | 2011 | 1060 | 0.07 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.07 | Why? |
| Antibodies, Bacterial | 1 | 2007 | 510 | 0.07 | Why? |
| Liver | 1 | 2018 | 4007 | 0.07 | Why? |
| Vaccination | 3 | 2019 | 19050 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Cell Proliferation | 1 | 2011 | 1973 | 0.06 | Why? |
| Erythrocytes | 1 | 2008 | 617 | 0.06 | Why? |
| Methyltransferases | 1 | 2008 | 720 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.06 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.06 | Why? |
| Cell Movement | 2 | 2019 | 695 | 0.06 | Why? |
| Aged | 14 | 2018 | 215776 | 0.06 | Why? |
| Mobile Applications | 1 | 2017 | 3032 | 0.06 | Why? |
| Drug Resistance | 2 | 2018 | 395 | 0.06 | Why? |
| Eye Diseases | 1 | 2012 | 1150 | 0.05 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.05 | Why? |
| Immune System | 1 | 2011 | 1479 | 0.05 | Why? |
| Opportunistic Infections | 2 | 2017 | 602 | 0.05 | Why? |
| Nervous System Diseases | 1 | 2019 | 4092 | 0.05 | Why? |
| Cohort Studies | 6 | 2018 | 36005 | 0.05 | Why? |
| Neoplasms, Experimental | 1 | 2019 | 67 | 0.05 | Why? |
| Lymphatic Vessels | 1 | 2019 | 43 | 0.05 | Why? |
| Mucoproteins | 1 | 2018 | 32 | 0.05 | Why? |
| Abdominal Abscess | 1 | 2018 | 41 | 0.05 | Why? |
| Oxadiazoles | 1 | 2018 | 41 | 0.05 | Why? |
| Epithelial Cells | 1 | 2011 | 3508 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Drug Approval | 2 | 2019 | 1325 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.05 | Why? |
| Indans | 1 | 2018 | 54 | 0.04 | Why? |
| Epoxy Compounds | 1 | 2017 | 21 | 0.04 | Why? |
| Mice, Inbred DBA | 1 | 2017 | 56 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 8811 | 0.04 | Why? |
| Sexual Dysfunctions, Psychological | 1 | 2018 | 37 | 0.04 | Why? |
| Comparative Effectiveness Research | 1 | 2018 | 178 | 0.04 | Why? |
| Oxylipins | 1 | 2017 | 29 | 0.04 | Why? |
| Cancer Vaccines | 1 | 2019 | 136 | 0.04 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2017 | 65 | 0.04 | Why? |
| Ankle | 1 | 2017 | 66 | 0.04 | Why? |
| Delayed-Action Preparations | 1 | 2019 | 291 | 0.04 | Why? |
| Administration, Topical | 1 | 2018 | 272 | 0.04 | Why? |
| Europe | 3 | 2020 | 12702 | 0.04 | Why? |
| Symporters | 1 | 2017 | 80 | 0.04 | Why? |
| Mice, Nude | 1 | 2017 | 340 | 0.04 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2017 | 144 | 0.04 | Why? |
| Drug Dosage Calculations | 1 | 2018 | 243 | 0.04 | Why? |
| Lipocalin-2 | 1 | 2017 | 156 | 0.04 | Why? |
| Life Style | 2 | 2019 | 2708 | 0.04 | Why? |
| Erectile Dysfunction | 1 | 2017 | 141 | 0.04 | Why? |
| Cell Line | 1 | 2011 | 12040 | 0.04 | Why? |
| Stress, Psychological | 1 | 2019 | 10231 | 0.04 | Why? |
| ROC Curve | 2 | 2018 | 6024 | 0.04 | Why? |
| Social Media | 1 | 2017 | 5798 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2018 | 696 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.04 | Why? |
| Markov Chains | 1 | 2017 | 502 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2018 | 6543 | 0.04 | Why? |
| Drainage | 1 | 2018 | 414 | 0.04 | Why? |
| Tacrolimus | 1 | 2018 | 435 | 0.04 | Why? |
| United States | 2 | 2019 | 46150 | 0.04 | Why? |
| Depression | 1 | 2019 | 14116 | 0.04 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.03 | Why? |
| Quality-Adjusted Life Years | 1 | 2017 | 511 | 0.03 | Why? |
| Models, Economic | 1 | 2017 | 316 | 0.03 | Why? |
| RNA, Ribosomal, 16S | 1 | 2017 | 793 | 0.03 | Why? |
| Gene Expression Profiling | 2 | 2019 | 3788 | 0.03 | Why? |
| Venous Thromboembolism | 1 | 2012 | 4273 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2019 | 11497 | 0.03 | Why? |
| Sexual Health | 1 | 2019 | 419 | 0.03 | Why? |
| Cholagogues and Choleretics | 1 | 2012 | 11 | 0.03 | Why? |
| Biological Factors | 1 | 2017 | 276 | 0.03 | Why? |
| Reproductive Health | 1 | 2019 | 473 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Anxiety | 1 | 2019 | 17311 | 0.03 | Why? |
| T-Lymphocytes | 1 | 2011 | 6670 | 0.03 | Why? |
| Serologic Tests | 1 | 2007 | 4359 | 0.03 | Why? |
| Interleukin-6 | 1 | 2011 | 7522 | 0.03 | Why? |
| Liver Cirrhosis | 1 | 2005 | 1810 | 0.03 | Why? |
| Ursodeoxycholic Acid | 1 | 2012 | 25 | 0.03 | Why? |
| Infertility, Male | 1 | 2018 | 322 | 0.03 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.03 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.03 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 92 | 0.03 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.03 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.03 | Why? |
| Metagenomics | 1 | 2018 | 823 | 0.03 | Why? |
| Mice, 129 Strain | 1 | 2011 | 36 | 0.03 | Why? |
| Acute Disease | 1 | 2005 | 6029 | 0.03 | Why? |
| Hygiene | 1 | 2019 | 987 | 0.03 | Why? |
| Quality Indicators, Health Care | 1 | 2017 | 580 | 0.03 | Why? |
| Permeability | 1 | 2012 | 238 | 0.03 | Why? |
| Hemoglobins | 1 | 2018 | 958 | 0.03 | Why? |
| Interleukin-33 | 1 | 2012 | 120 | 0.03 | Why? |
| Patient Acuity | 1 | 2018 | 1755 | 0.03 | Why? |
| Myofibroblasts | 1 | 2011 | 61 | 0.03 | Why? |
| Attitude of Health Personnel | 1 | 2009 | 4741 | 0.03 | Why? |
| Dilatation | 1 | 2012 | 181 | 0.03 | Why? |
| Withholding Treatment | 1 | 2017 | 798 | 0.03 | Why? |
| Bone Density Conservation Agents | 1 | 2012 | 209 | 0.03 | Why? |
| Blotting, Western | 1 | 2012 | 863 | 0.03 | Why? |
| Health Care Surveys | 1 | 2020 | 2942 | 0.03 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 343 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 7868 | 0.02 | Why? |
| Guanine Nucleotides | 1 | 2008 | 8 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Caco-2 Cells | 1 | 2012 | 1236 | 0.02 | Why? |
| Health Surveys | 1 | 2020 | 2841 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2019 | 5814 | 0.02 | Why? |
| Fatigue | 1 | 2019 | 2479 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| Microbiota | 1 | 2017 | 1240 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2019 | 53120 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.02 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2017 | 3347 | 0.02 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.02 | Why? |
| Canada | 1 | 2018 | 6018 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2018 | 3803 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Health Services Needs and Demand | 1 | 2019 | 3419 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2011 | 2275 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2012 | 3395 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Surgical Procedures, Operative | 1 | 2019 | 2662 | 0.02 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.01 | Why? |
| Population Surveillance | 1 | 2018 | 4967 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Internet | 1 | 2018 | 6204 | 0.01 | Why? |
| Sex Factors | 1 | 2015 | 11014 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 11367 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Anticoagulants | 1 | 2012 | 9563 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 13720 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2012 | 10083 | 0.01 | Why? |